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Lipocalin-2 is increased in progressive
multiple sclerosis and inhibits
remyelination
ABSTRACT
Objective: We aimed to examine the regulation of lipocalin-2 (LCN2) in multiple sclerosis (MS) and
its potential functional relevance with regard to myelination and neurodegeneration.
Methods: We determined LCN2 levels in 3 different studies: (1) in CSF and plasma from a case-
control study comparing patients with MS (n 5 147) with controls (n 5 50) and patients with
relapsing-remitting MS (n 5 75) with patients with progressive MS (n 5 72); (2) in CSF and brain
tissue microdialysates from a case series of 7 patients with progressive MS; and (3) in CSF at
baseline and 60 weeks after natalizumab treatment in a cohort study of 17 patients with pro-
gressive MS. Correlation to neurofilament light, a marker of neuroaxonal injury, was tested. The
effect of LCN2 on myelination and neurodegeneration was studied in a rat in vitro neuroglial cell
coculture model.
Results: Intrathecal production of LCN2was increased predominantly in patients with progressive
MS (p , 0.005 vs relapsing-remitting MS) and displayed a positive correlation to neurofilament
light (p 5 0.005). Levels of LCN2 in brain microdialysates were severalfold higher than in the
CSF, suggesting local production in progressive MS. Treatment with natalizumab in progressive
MS reduced LCN2 levels an average of 13% (p , 0.0001). LCN2 was found to inhibit remyeli-
nation in a dose-dependent manner in vitro.
Conclusions: LCN2 production is predominantly increased in progressive MS. Although this mod-
erate increase does not support the use of LCN2 as a biomarker, the correlation to neurofilament
light and the inhibitory effect on remyelination suggest that LCN2 might contribute to neurode-
generation through myelination-dependent pathways. Neurol Neuroimmunol Neuroinflamm
2016;3:e191; doi: 10.1212/NXI.0000000000000191
GLOSSARY
BSA5 bovine serum albumin;DIV5 days in vitro; EAE5 experimental autoimmune encephalomyelitis; INDC5 inflammatory
neurologic disease controls; LCN2 5 lipocalin-2;MD 5 microdialysates; MOG 5 myelin oligodendrocyte glycoprotein; MS 5
multiple sclerosis; NFL 5 neurofilament light; PBS 5 phosphate-buffered saline; PPMS 5 primary progressive MS; RR 5
relative recovery; RRMS 5 relapsing-remitting MS; SC 5 symptomatic controls; SMI-31 5 phosphorylated neurofilament;
SPMS 5 secondary progressive MS; TNF 5 tumor necrosis factor.
The recent progress in the understanding of the pathophysiology and therapeutic options in
multiple sclerosis (MS) pertains mainly to earlier relapsing-remitting MS (RRMS) stages. Our
understanding of later disease stages is much more limited, and there is an urgent need to iden-
tify biomarkers of pathophysiologic pathways that can increase our knowledge and possibly lead
to the identification of new therapeutic targets.1,2
Lipocalin-2 (LCN2) is a 25-kDa protein that was first identified as an acute phase protein
stored and secreted by neutrophils.3,4 It has now been ascribed multiple signaling roles, such
as iron delivery, cell survival/death, differentiation, and inflammation, in physiologic and
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pathologic conditions.5 Recently, a number of
studies have pointed to a role for LCN2 in the
CNS as well; in experimental models and cell
culture systems, LCN2 induces reactive astro-
cytosis, neuronal migration, and death, and it
also possibly has a detrimental effect on
oligodendrocytes.6–10 It also promotes M1
polarization of microglia and mediates their
deramification and apoptosis.11,12 Studies in
experimental autoimmune encephalomyelitis
(EAE) have suggested functional roles for
LCN2, with regulatory effects on disease
severity, proliferation of T cells, and demyeli-
nation.13–16 Of note, LCN2 has been shown to
be increased in a small cohort of patients with
progressive disease (compared with RRMS).15
Therefore, in a case-control study, we com-
pared the intrathecal production of LCN2
between patients with RRMS, patients with
progressive MS, and controls, and the results
prompted us to further investigate its regula-
tion and potential functional relevance in
progressive MS.
METHODS Study design and patient samples. We deter-
mined LCN2 levels in 3 different studies. First, we compared
LCN2 production between patients with MS and controls and
between patients with RRMS and progressive MS in a case-
control study. CSF and plasma samples were obtained from an
in-house biobank (Karolinska University Hospital, Sweden)
containing samples collected during routine neurologic workups
from 2003 to 2012. Demographic data of the patients included
in this study are presented in table e-1 at Neurology.org/nn. A
total of 197 patients were included, of which 147 were patients
with MS fulfilling the McDonald criteria (RRMS 5 75 [relapse
5 19, remission5 56]; secondary progressive MS [SPMS]5 49;
primary progressive MS [PPMS]5 23). SPMS was defined as an
initial relapsing-remitting disease course followed by more than
12 months of continuous worsening ($0.5 Expanded Disability
Status Scale point) not explained by relapses. At time of sampling,
none of the patients had received immunomodulatory treatment.
Control groups were composed of symptomatic controls (SC)
(n 5 39; sensory symptoms 5 34, dizziness/vertigo 5 3,
tension headache 5 2) and inflammatory neurologic disease
controls (INDC) (n 5 11; systemic lupus erythematosus 5 4,
herpes encephalitis 5 2, sarcoidosis 5 1, anti-NMDA receptor
encephalitis 5 1, progressive multifocal encephalopathy 5 1,
demyelinating disease of unknown etiology 5 1, myelopathy of
unknown etiology5 1) according to the guidelines for biomarker
studies in MS.17 We used SC and INDC to investigate whether
LCN2 can be used as a biomarker to distinguish between patients
with MS and patients with similar neurologic symptoms and
patients with similar CSF laboratory parameters, respectively.
Second, we determined LCN2 levels in the CSF and
microdialysates (MD) in a case series study of 7 patients with
SPMS who received intrathecal delivery of rituximab (Umeå
University, NCT01719159). In this study, microdialysis
catheters were used to monitor the treatment effect. They were
inserted at baseline (day 0) in periventricular brain tissue and
perfused with Plasmodex solution for 7 days. CSF was collected
by lumbar puncture 1–2 days before the operative procedure and
MD were collected 6 times a day. Finally, we measured the CSF
levels of LCN2 in an open-label trial of natalizumab in
progressive MS. In this cohort, LCN2 was determined in CSF
collected from 10 patients with PPMS and 7 patients with SPMS
at baseline and after 60 weeks of treatment with natalizumab. The
details of the study design and outcome have been previously
published.18
Standard protocol approvals, registrations, and patient
consents. The regional ethical vetting boards of Stockholm
(main study; 2003/2-548), Umeå (MD substudy; 2009/2107-
31-2), and Copenhagen (natalizumab substudy; 2012-334-
32M) approved the study procedures, and written informed
consent was obtained from all patients.
Measurements and relative recovery of LCN2 by
microdialysis. CSF samples were centrifuged (300g) immedi-
ately after sampling, aliquoted, and stored at 280°C until anal-
ysis. Levels of neurofilament light (NFL) in the main CSF cohort
were obtained from a previously published dataset.19 LCN2 levels
in CSF and plasma were measured using a commercially available
ELISA kit (R&D Systems, Minneapolis, MN). Because LCN2
values reported in the literature were higher than those measured
in our material,14,20 we also ran approximately one-seventh of the
CSF samples, including all groups of patients except for INDC,
on an ELISA kit from Bioporto (Copenhagen, Denmark). The
LCN2 levels measured with the Bioporto kit were 30% higher on
average but correlated very well with the levels obtained from the
R&D ELISA (R2 5 0.93) and were adjusted to the more
conservative estimate. Measurements were optimized and
performed for LCN2 using a 1:1.2 CSF to phosphate-buffered
saline (PBS) dilution and a 1:200 plasma to PBS dilution. For the
MD samples and their matched CSF obtained by lumbar
puncture, the Bioporto ELISA was used because of the higher
sensitivity and the need to work with higher dilutions because of
the smaller collected volumes.
LCN2 is a molecule that exists in high concentrations in the
blood, and passive leakage to the CNS may contribute to the lev-
els detected in the intrathecal compartment. Therefore, we calcu-
lated the LCN2 index, which likely better reflects the intrathecal
production of LCN2, according to the formula used to calculate
the IgG index (i.e., LCN2 index: [CSF LCN2/CSF albumin]/
[plasma LCN2/plasma albumin]) and using samples obtained at
the same time for each patient. CSF was available for LCN2
measurements from all patients. Patients for whom LCN2 index
was not calculated because of random missingness of 1 or more of
the other 3 parameters were excluded from the analyses (SC5 2,
INDC 5 2, RRMS 5 3, SPMS 5 18, PPMS 5 5).
To estimate the real in vivo brain tissue concentrations of
LCN2, the relative recovery (RR) of LCN2 by microdialysis
was calculated in an in vitro experiment. Recombinant human
LCN2 (Sigma-Aldrich, St. Louis, MO) was used for the RR
experiment at concentrations 1 time, 10 times, and 100 times
the maximum concentration obtained in the MD samples from
patients. Recombinant LCN2 was diluted in Ringer solution with
0.2 mg/mL bovine serum albumin (BSA) to form an “artificial
interstitial fluid” compartment. AnMD catheter was immersed in
the artificial solution and then perfused by Plasmodex solution by
the same MD pump system as in the patients. After flush priming
of the catheter, the MD fluid was drained to a waste tube for at
least 40 minutes before sampling. Subsequently, MD were col-
lected for 2 lots of 2 hours. The LCN2 concentrations in the
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artificial solution and the collected MD were measured by ELISA
(Bioporto).
Myelinating cultures. In vitro rat myelinating cultures were es-
tablished as described previously.21 Cultures were maintained at
37°C/7% CO2 and fed thrice weekly by replacing half the culture
medium with fresh differentiation media. After 12 days in vitro
(DIV), insulin was omitted from the culture medium to promote
myelination, with further culturing for up to 30 days. Myelinat-
ing cultures were either untreated or treated daily with 10 ng/mL,
100 ng/mL, or 1,000 ng/mL of recombinant rat LCN2 (R&D
Systems) from 18 DIV (early) or 24 DIV (late) and for 10 or 6
days, respectively. Experiments were performed 3 times.
Immunochemistry. The following antibodies were used: mouse
monoclonal SMI-31 (phosphorylated neurofilament, Abcam,
Cambridge, UK), Z2 (anti-MOG [myelin oligodendrocyte
glycoprotein]),22 and rabbit polyclonal NG2 (chondroitin
sulphate proteoglycan, Millipore, Billerica, MA). Secondary
antibodies were labeled with Alexa Fluor 488 or Alexa Fluor 555
(Invitrogen, Waltham, MA). To visualize extracellular epitopes on
live cells, primary antibody was applied for 30 minutes at 4°C. After
repeated washing in ice-cold Dulbecco’s modified eagle medium,
subsequent steps were at room temperature. Cells were fixed in 4%
paraformaldehyde for 20 minutes at room temperature. For
cytoplasmic antigens, cells were permeabilized with 0.5% Triton
X-100/PBS for 10 minutes (Sigma-Aldrich) followed by 1 hour in
1% BSA/10% normal goat serum/0.3M glycine. This was followed
by application of primary antibodies for 1 hour, repeated PBS
washing, application of appropriate secondary antibodies for
15 minutes, washing with PBS and distilled H2O, and mounting
in Vectashield (Vector Laboratories, Burlingame, CA).
Image analysis. In each case, a minimum of 10 images (103
magnification) were acquired from 3 coverslips using an Olympus
B351 fluorescent microscope and Image-Pro software (Media
Cybernetics, Rockville, MD). Axonal density was quantified
using ImageJ software (NIH systems, version 1.41) as the relative
area positive for SMI-31 (SMI-311). To calculate the percentage of
myelinated axons, MOG immunoreactive (MOG1) myelin
sheaths were determined using the BRAINS BATCH algorithm,
which uses pattern recognition software to distinguish between
linear myelinated internodes and oligodendrocyte cell bodies. To
quantify cell numbers, a minimum of 30 images were taken from 3
coverslips (203 magnification) and staining density was quantified
using ImageJ. Cell counts were expressed as a percentage of the total
NG21 pixels within the total field.
Statistical analyses. Analyses were performed with Microsoft
Excel and GraphPad Prism 5.0. Comparisons were done by
1-way analysis of variance with Bonferroni post hoc test. The
mean values were used to calculate fold changes and are shown
in the graphs. Correlation analyses were performed using the
Pearson test.
RESULTS Intrathecal production of LCN2 is increased
in progressive MS and correlates to NFL. Albumin quo-
tient was significantly higher in patients with MS
than in SC (1.25-fold), but there was no difference
between MS subtypes. Plasma LCN2 was higher in
INDC than in both SC and patients with MS
(figure 1). The CSF LCN2 levels, as well as the
LCN2 index, were higher (1.51- and 1.25- fold,
respectively) in patients with MS than in SC
(figure 2, A and B). Upon stratification for the MS
disease subtypes, we found that the CSF levels and
the LCN2 index were higher in patients with SPMS
(1.27- and 1.39-fold, respectively) and patients with
PPMS (1.32- and 1.27-fold, respectively) than in
patients with RRMS, although the LCN2 index
comparison between PPMS and RRMS was not
statistically significant (figure 2, C and D). The
LCN2 index, but not CSF LCN2, was higher in
remission than in relapse (figure 2, E and F). The
higher levels of LCN2 in progressive MS were
replicated in a separate cohort of 22 patients with
RRMS and 24 patients with SPMS (1.39-fold, p ,
0.001, data not shown). Because we found that
LCN2 is increased in progressive MS, we next
sought to study a possible functional role of LCN2
in human progressive disease and found that the
LCN2 index correlated significantly to NFL (figure
3A). LCN2 did not correlate to age in all MS disease
subtypes, and NFL levels were higher in RRMS than
in SPMS (data not shown).
LCN2 is found in high concentrations in in vivo brain
tissue and its production is modestly reduced by
natalizumab. We next investigated whether the higher
LCN2 levels reflect a local production in the CNS in
progressive disease and whether LCN2 is regulated by
adaptive immune pathways. Determination of LCN2
levels in MD collected at day 1, 2, and 3 after place-
ment of MD catheters revealed much higher levels
than those found in CSF from the same patients.
RR as calculated by the in vitro experiment was 9%
on average. This is similar to the RR measured in
in vitro recovery studies with the 100-kDa cutoff
MD membranes used for other molecules with
similar molecular weights.23 Collectively, the
estimated local brain LCN2 concentrations were
much higher than those in CSF, ranging from 13
times to 853 times the CSF values, which
corresponds to concentrations in the range of 12–
656 ng/mL (table 1).
Determination of LCN2 levels in patients with
PPMS and SPMS participating in an open-label study
with natalizumab18 revealed a decrease of LCN2 60
weeks after treatment, but only by 13.9% on average
(figure 3B).
LCN2 inhibits myelination in neuroglial cell cocultures.
Because demyelination and impaired remyelination
are important characteristics of MS pathophysiology,
we next studied the effect of LCN2 in myelinating
cultures. Addition of 100 ng/mL of LCN2 at 18
DIV inhibited myelination by 42.4%, whereas addi-
tion of 1,000 ng/mL resulted in a 78.9% inhibition
(figure 4A). In contrast, exposure to 1,000 ng/mL
of LCN2 at a later stage (24–30 DIV), when myeli-
nation in the cocultures had already occurred, did not
affect myelination (figure 4B). LCN2 did not have
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any effect on oligodendroglial progenitor cell num-
bers or axonal density (figure e-1).
DISCUSSION Because EAE studies suggested that
LCN2 is a potentially important molecule for CNS
autoimmunity, a biomarker for MS, and increased
in the progressive form of MS, we measured LCN2
in a large case-control study of patients with MS
and controls and found CSF LCN2 levels and
intrathecal LCN2 production to be increased in
patients with MS, predominantly those with
progressive disease. This finding was subsequently
replicated in an independent cohort of patients.
Our data are in accordance with the increased CSF
LCN2 levels but not the increased plasma LCN2
levels reported previously in much smaller
cohorts.14,15 However, plasma LCN2 levels were
increased in INDC, in line with previous
publications.24,25 However, the increase of the
LCN2 index in patients with MS compared to
controls and in progressive disease compared to
RRMS is relatively moderate, with an overlap
between the groups. This suggests that LCN2 is
likely not a suitable biomarker for clinical diagnosis
and prognosis; rather, its increase and correlation to
NFL in SPMS indicate a functional role in this
Figure 1 Plasma LCN2 levels and albumin quotient in patients with MS and controls
Plasma levels of lipocalin-2 (LCN2) and albumin quotient in (A, B) symptomatic controls (SC), inflammatory neurologic dis-
ease controls (INDC), and patients with multiple sclerosis (MS); in (C, D) patients with relapsing-remitting MS (RRMS), sec-
ondary progressive MS (SPMS), and primary progressive MS (PPMS); and in (E, F) patients in RRMS remission and RRMS
relapse. *p , 0.05, **p , 0.01, and ****p , 0.0001.
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disease form. NFL is an axonal protein and a marker
that is increased during all disease stages in MS; it is
highest during relapses but is also increased in
progressive disease and correlates with disease
activity.26,27 Therefore, the correlation between
LCN2 and NFL is interesting because it is observed
in a disease stage for which our knowledge about
pathogenic processes is still limited. A detrimental
effect of LCN2 on axonal degeneration in progressive
MS can be induced by several mechanisms, as LCN2
has been shown to modulate CNS inflammation,
induce neuronal cell death, regulate dendritic spine
formation, and, importantly, modulate iron availability
and transfer to the cells, which has been suggested to
be of particular importance for demyelination and
neurodegeneration in progressive MS.6,13,20,28–31
We also describe an effect of LCN2 in inhibiting
remyelination, but not inducing demyelination, in
in vitro cell cultures in concentrations corresponding
to in vivo brain tissue levels of 5 of 7 patients with
progressive disease. This finding suggests that
LCN2 might induce neurodegeneration through
myelination-dependent pathways, a mechanism that
has been well described in MS in previous studies.32,33
Even though axonal density in cocultures was not
affected by inhibition of remyelination through
LCN2, it should be noted that it is difficult to trans-
late acute treatment data in an experimental in vitro
Figure 2 LCN2 protein levels in CSF and LCN2 index in patients with MS and controls
CSF levels of lipocalin-2 (LCN2) and LCN2 index values in (A, B) symptomatic controls (SC), inflammatory neurologic disease
controls (INDC), and patients with multiple sclerosis (MS); in (C, D) patients with relapsing-remitting MS (RRMS), secondary
progressive MS (SPMS), and primary progressive MS (PPMS); and in (E, F) patients in RRMS remission and RRMS relapse.
*p , 0.05 and ***p , 0.001.
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model to chronic exposure over extensive time peri-
ods in the human brain tissue in vivo. The fact that
LCN2 might inhibit remyelination is also important
because impaired remyelination is a major compo-
nent of MS pathology for which there are currently
no good biomarkers or therapeutic options, although
such treatments are in early stages of clinical trials.
In terms of the cause of the increased LCN2 levels
in progressive MS, recent studies suggest a shift to a
Th17-mediated response and also higher levels of
tumor necrosis factor (TNF) in progressive MS, while
both interleukin-17 and TNF may drive expression of
LCN2 through effects on its promoter.34–37 In an
effort to further study the production of LCN2 and
especially to dissect its regulation by adaptive vs
innate immune pathways, we observed that treatment
with natalizumab, which effectively targets lympho-
cyte migration into the CNS and drastically reduces
NFL levels in RRMS,38 had only a limited effect in
terms of reducing LCN2 CSF levels. This finding
suggests that production of LCN2 is in large part
independent of adaptive immune responses and also
highlights pathways of regulation other than those
suggested by EAE studies, in which natalizumab dras-
tically reduced LCN2 production in the CNS.14 Neu-
trophils may also play a key role in this context,
because neutrophils are a source of LCN2 and are
not blocked by natalizumab. In experimental models,
neutrophils play a significant role in clinical onset of
EAE, whereas their role in MS, although not clarified
in detail, is suggested to be more prominent in later
disease stages.39 On the other hand, our data are in
accordance with recent reports on experimental CNS
disease models and human neuropathologic studies
that show that infiltrating monocytes/macrophages
and neutrophils, as well as astrocytes and neurons
(but not lymphocytes), produce LCN2.6,14,15,20 It will
thus be important for future studies to investigate the
immune cell or molecular pathways that regulate
LCN2 in progressive disease to disclose additional
pathophysiologic mechanisms that differ from
RRMS.
To further investigate the regulation of LCN2
in vivo in progressive MS, we measured LCN2 levels
in MD and CSF and found them to be severalfold
higher in brain interstitial fluid than in CSF in all 7
patients. In our MD measurements, we included 2
different time points from patient 2 (days 0 and 3)
and patient 3 (days 1 and 3) and observed a temporal
increase and decrease of LCN2 levels, respectively.
This observed difference in kinetics possibly indicates
that high local tissue production (not serum leakage
and/or catheter-induced trauma) is the cause of high
LCN2 levels. This is also supported by the fact that
Table 1 LCN2 is severalfold higher in the in vivo brain tissue as seen by comparison of LCN2 levels in MD vs
CSF
Patient 1 Patient 2 Patient 2 Patient 3 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Days after operation 1 0 3 1 3 3 2 1 1
MD LCN2 59,058 3,485 15,588 9,933 2,054 46,186 56,203 1,051 5,915
(MD LCN2)/RR 656,139 38,719 173,186 110,359 22,823 513,127 624,414 11,675 65,718
LP CSF LCN2 769 1,734 1,597 1,269 1,150 907 913
Abbreviations: LCN2 5 lipocalin-2; LP CSF 5 CSF obtained via lumbar puncture; MD 5 microdialysates; RR 5 relative
recovery.
Figure 3 LCN2 correlation to NFL and natalizumab treatment effect on CSF LCN2 levels in SPMS
(A) Correlation between neurofilament light (NFL) and lipocalin-2 (LCN2) index in secondary progressivemultiple sclerosis (SPMS).
(B) Effect of 6 months of treatment with natalizumab on CSF LCN2 levels in progressive multiple sclerosis. ****p , 0.0001.
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the estimated MD LCN2 levels in some patients were
severalfold higher than the serum values measured in
the larger cohort. Because studies that have reported
the levels of a molecule in both brain interstitial fluid
and CSF in MS are rare, more research is needed to
further explore the relationship between brain inter-
stitial fluid and CSF in MS for LCN2 and other mol-
ecules and/or biomarkers. However, regarding
LCN2, the severalfold higher levels in the interstitial
fluid are not surprising in light of experimental data
showing high local expression in the CNS and the
described autocrine functions, and suggest that
LCN2 is produced, secreted, and used in the brain
tissue, with only a small fraction circulating in the
CSF.7,11,15,40
We find that LCN2 is predominantly increased in
the intrathecal compartment of patients with pro-
gressive MS and that this increase reflects a local tissue
production, as indicated by the MDmeasurements in
in vivo brain tissue. Furthermore, LCN2 inhibits
remyelination in vitro and correlates to neurodegen-
eration in SPMS. These observations imply a detri-
mental role of LCN2 in progressive MS, where it is
locally produced in the CNS and might induce axonal
degeneration, possibly through inhibition of remyeli-
nation. More studies in progressive disease models
and/or MS to further elucidate the pathways that
modulate the regulation and effect of LCN2 in pro-
gressive MS are warranted.
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